pieris.com - יחס שווי כולל של החברה להכנסות PVLA

Pieris Pharmaceuticals (PVLA) is a biopharmaceutical startup whose success relies on anti-kallikrein test results and external funding. This chart on GURU.Markets illustrates the enterprise value assessment via EV/Sales, where 0.00 is the current value of the metric. The business model is based on R&D design, while production and clinical trials are fully outsourced to reliable contractors to ensure flexible responses to market demands.
PVLA (Pieris Corp): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Stress testing assets requires analyzing business value without distortions from credit load. Pieris Pharmaceuticals (PVLA) focuses on developing Anticalin proteins for the treatment of oncology and respiratory pathologies. The EV/Sales history demonstrates the market price of every dollar of revenue, excluding the influence of capital structure. This multiple allows for the comparison of market capitalization with actual sales. An anomalous decline in the indicator may signal a risk of falling future revenues.